Sestrin 2 controls the cardiovascular aging process via an integrated network of signaling pathways

•The stress-inducible Sestrin 2 protein acts as an anti-aging agent.•Preclinical experiments suggest that Sestrin2 maybe cardioprotective.•Expression of Sesn2 decreases with age.•Reduction of Sestrin2 signal transduction is implicated in cardiovascular diseases.•The Sestrin2 pathway may be a target...

Full description

Saved in:
Bibliographic Details
Published in:Ageing research reviews 2020-09, Vol.62, p.101096-101096, Article 101096
Main Authors: Liu, Yunxia, Du, Xiaoyu, Huang, Zhehao, Zheng, Yang, Quan, Nanhu
Format: Article
Language:English
Subjects:
Aging
Cardiac aging
Cardiovascular disease
Humans
Nuclear Proteins
Sestrin 2
Signal Transduction
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:•The stress-inducible Sestrin 2 protein acts as an anti-aging agent.•Preclinical experiments suggest that Sestrin2 maybe cardioprotective.•Expression of Sesn2 decreases with age.•Reduction of Sestrin2 signal transduction is implicated in cardiovascular diseases.•The Sestrin2 pathway may be a target to treat age-associated cardiovascular disease. As an inevitable biological process, cardiovascular aging is the greatest risk factor for cardiovascular diseases (CVDs). Sestrin 2 (Sesn2), a stress-inducible and age-related protein associated with various stress conditions, plays a pivotal role in slowing this process. It acts as an anti-aging agent, mainly through its antioxidant enzymatic activity and regulation of antioxidant signaling pathways, as well as by activating adenosine monophosphate-activated protein kinase and inhibiting mammalian target of rapamycin complex 1. In this review, we first introduce the biochemical functions of Sesn2 in the cardiovascular aging process, and describe how Sesn2 expression is regulated under various stress conditions. Next, we emphasize the role of Sesn2 signal transduction in a series of age-related CVDs, including hypertension, myocardial ischemia and reperfusion, atherosclerosis, and heart failure, as well as provide potential mechanisms for the association of Sesn2 with CVDs. Finally, we present the potential therapeutic applications of Sesn2-directed therapy and future prospects.
ISSN:1568-1637
1872-9649
DOI:10.1016/j.arr.2020.101096